At the same time, targeting BRD9 in AML inhibited its development and maintenance by immediately enhancing myeloid differentiation and impairing Myc pathway and ribosome biogenesis (Fig. 7 and Supplementary Fig. 12). The gene discussed is MYC; the disease is acute myeloid leukemia.